< Back | |
05 Jan 2016 | |
The Exchange had sought clarification from the company with respect to news article appearing in DNA on January 04, 2016 titled "Roche, Glenmark settle dispute over cancer drug".<BR><BR>The company replied stating "Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company." | |
View all announcements for GLENMARK PHARMACEUTICALS LTD. | Source: BSE India |